0.34
+0.0053(+1.61%)
Currency In USD
| Previous Close | 0.33 |
| Open | 0.32 |
| Day High | 0.35 |
| Day Low | 0.32 |
| 52-Week High | 3 |
| 52-Week Low | 0.22 |
| Volume | 686,624 |
| Average Volume | 6.6M |
| Market Cap | 13.92M |
| PE | -0.16 |
| EPS | -2.07 |
| Moving Average 50 Days | 0.37 |
| Moving Average 200 Days | 0.49 |
| Change | 0.01 |
If you invested $1000 in ProPhase Labs, Inc. (PRPH) 10 years ago, it would be worth $206.85 as of August 22, 2025 at a share price of $0.335. Whereas If you bought $1000 worth of ProPhase Labs, Inc. (PRPH) shares 5 years ago, it would be worth $265.95 as of August 22, 2025 at a share price of $0.335.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
ProPhase Labs Announces Filing of Definitive Proxy Statement and New Date for Special Meeting of Shareholders
GlobeNewswire Inc.
Aug 19, 2025 12:00 PM GMT
UNIONDALE, NY, Aug. 19, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation biotech, genomics and consumer products company, today announced that it filed a definitive proxy statement (“DEF 1
ProPhase Labs Announces Full USPTO Approval for Issuance of U.S. Patent Protecting Esophageal Adenocarcinoma Risk Assessment
GlobeNewswire Inc.
Aug 12, 2025 12:00 PM GMT
U.S. Patent No. 12379378-B2 protects biomarker-driven systems and methods to assess progression risk in Barrett’s esophagus and esophageal adenocarcinoma; issuance follows the successful BE-Smart™ test validation (>95% technical success) and, togethe
ProPhase Labs Inc. to Present Second Quarter 2025 Financial Results on August 13, 2025
GlobeNewswire Inc.
Aug 11, 2025 12:00 PM GMT
UNIONDALE, NY, Aug. 11, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”), a next generation biotech, genomics and consumer products company, announced today that they will be presenting second quarter 2025 f